Michigan Capital Network's recent acquisitions, including HistoSonics and Micro-LAM, highlight a thriving venture capital landscape in the state, driven by innovation in healthcare and technology.

Target Information

The recent acquisition of HistoSonics represents a significant milestone in the ongoing activities of Michigan Capital Network (MCN). Founded in 2009 as a spin-off from the University of Michigan, HistoSonics specializes in ultrasound-based medical technology, specifically the Edison Histotripsy System, which noninvasively targets and eliminates tumors. This innovative approach holds promise for patients facing critical health challenges and underscores the advancements in the healthcare sector driven by local start-ups.

Additionally, Micro-LAM, another key player within MCN's portfolio, was recently acquired by IDEX Corporation for $90 million. Established in 2017, Micro-LAM operates out of Portage and has carved a niche in advanced manufacturing technologies such as laser-assisted machining and precision diamond tools. These strategic acquisitions reflect the dynamic growth and potential within Michigan's entrepreneurial ecosystem.

Industry Overview in Michigan

Michigan's economy has a rich history in the agri-business sector, characterized by its diverse agricultural production including fruits, vegetables, and specialty crops. This agricultural base, combined with significant investment in technology and innovatio

View Source

Similar Deals

Abbott Exact Sciences

2026

Other In-Vivo Diagnostic & Testing Substances United States of America
Edwards Lifesciences JenaValve Technology

2026

Other Medical Devices & Implants United States of America
Fortified Health Security Latitude Information Security

2026

Other Healthcare Facilities & Services (NEC) United States of America
Sofinnova Partners Hemab Therapeutics

2025

Other Bio Therapeutic Drugs United States of America
Knack RCM PPM Partners

2025

Other Healthcare Facilities & Services (NEC) United States of America
LPOXY Therapeutics, Inc. Xeno Biosciences Inc.

2025

Other Bio Therapeutic Drugs United States of America

K5 Global, Bezos Expeditions, Wellington Management

invested in

HistoSonics

in 2025

in a Other deal

Disclosed details

Transaction Size: $2,250M

Enterprise Value: $2,250M

Equity Value: $2,250M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert